Phase 3 study for people with Muscular Dystrophy

Recruiting Phase 3

Sources: ClinicalTrials.gov Checked: 15 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 3
Sponsor Avidity Biosciences, Inc.
Registry number NCT07587242
Started 1 September 2026 Today 16 October 2026 Estimated completion 1 May 2029

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
The Children's Hospital at Westmead Westmead NSW Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 15 October 2026 · not medical advice

Who can join

Age 7 Years to 16 Years
Sex Male participants only
Healthy volunteers Not accepted
Enrolment target 70

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Key Inclusion Criteria:

* Ambulatory males with clinical and genetic diagnosis of DMD

* Acceptable genetic test confirming dystrophin gene mutation amenable to exon 44 skipping

* 7 to 16 years of age at time of consent

* TTR and NSAA assessment completed within the protocol specified parameters at Screening

* On a stable regimen of corticosteroids (including Vamolorone) for at least 6 months prior to Day 1. Steroid regimen must be anticipated to remain stable.

Key Exclusion Criteria:

* Previous treatment cell or gene therapy.

* Treatment with another oligonucleotide within 6 months of informed consent (not including COVID-19 RNA vaccines).

* Lab values outside of the protocol specified range at Screening

* If on any of the following treatments (growth hormone, testosterone or givinostat), participants must be on a stable regimen and must plan to maintain it for the duration of the study. Participants will be excluded if regimen stability prior to informed consent is as follows:

* Less than 1 month, for growth hormone and/or testosterone

* Less than 6 months for givinostat

Dates on the record

Started 1 September 2026
Estimated completion 1 May 2029
Registry last updated 13 October 2026
Checked by Voxsanity 15 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 13 October 2026.
  • This page last checked by Voxsanity: 15 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.